Alexander Zheleznyak

Alexander Zheleznyak

Auto-generated profile, based on publicly available information

Alexander Zheleznyak

Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2023 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
DFDouglas V. Faget
Douglas V. Faget
XLXianmin Luo
Xianmin Luo
MIMatthew Inkman
Matthew Inkman
QRQihao Ren
Qihao Ren
XSXinming Su
Xinming Su
SSSheila A. Stewart
Sheila A. Stewart
Metastatic breast cancer is an intractable disease that responds poorly to immunotherapy. We show that p38MAPKα inhibition (p38i) limits tumor growth by reprogramming the metastatic tumor microenvironment in a CD4+ T cell-, IFNγ-, and macrophage-dependent manner. To identify targets that further increased p38i efficacy, we utilized a stromal labeling approach and single-cell RNA sequencing. Thus, we combined p38i and an OX40 agonist that synergistically reduced metastatic growth and increased overall survival. Intriguingly, patients with a p38i metastatic stromal signature had better overall survival that was further improved by the presence of an increased mutational load, leading us to ask if our approach would be effective in antigenic breast cancer. The combination of p38i, anti-OX40, and cytotoxic T-cell engagement cured mice of metastatic disease and produced long-term immunologic memory. Our findings demonstrate that a detailed understanding of the stromal compartment can be used to design effective antimetastatic therapies. Significance: Immunotherapy is rarely effective in breast cancer. We dissected the metastatic tumor stroma, which revealed a novel therapeutic approach that targets the stromal p38MAPK pathway and creates an opportunity to unleash an immunologic response. Our work underscores the importance of understanding the tumor stromal compartment in therapeutic design. This article is highlighted in the In This Issue feature, p. 1275

14 January 2026 in Blood Advances
Verified
Journal Article
Open access
MDMichael R. Dyer
Michael R. Dyer
AZAlex Zheleznyak
Alex Zheleznyak
ETErin N. Teubner
Erin N. Teubner
JPJulie L. Prior
Julie L. Prior
BMBrad Manion
Brad Manion
MSMonica Shokeen
Monica Shokeen
Multiple myeloma (MM) is a plasma cell malignancy characterized by bone pain and end-organ failure. A major challenge in treating MM is therapeutic resistance. CD38-targeted immunotherapies, such as daratumumab, have significantly improved outcomes; however, variable responses, resistance, and relapse remain vital challenges. We hypothesized that loss of CD38 drives a more aggressive phenotype and resistance to therapy. To test this, we developed a CD38 knockout (KO) clone of a human MM cell line and evaluated it in immunodeficient mice. Mice with CD38 KO tumors exhibited an increased tumor burden and reduced survival compared with those with CD38 wild-type (WT) tumors. Multimodal imaging and histologic analyses revealed increased osteolytic lesions caused by CD38 KO tumors, while [18F]-fluorodeoxyglucose positron emission tomography demonstrated elevated metabolic activity and tracer uptake. Mice with CD38 KO tumors also developed bilateral renal metastases, whereas none were observed in WT tumors. Blood analysis showed elevated markers of disease progression and renal dysfunction, and cytokine profiling identified increased proinflammatory cytokines within the bone microenvironment. RNA sequencing identified marked transcriptional changes, with enrichment of pathways involving cell adhesion, cytokine signaling, and migration. Daratumumab-resistant MM.1S cells mirrored CD38 KO cells with reduced cell cycle progression and dexamethasone sensitivity, underscoring the microenvironment’s role in driving aggressiveness, and implicating CD38 loss as a possible mediator of cross-resistance. Overall, these findings demonstrate that CD38 loss drives an aggressive MM phenotype characterized by bone degradation, renal metastasis, and reduced survival, highlighting the need to develop strategies to target CD38-deficient clones and identifying RNA signatures as potential regulators of this phenotype.

31 July 2025 in EJNMMI Research
Verified
Journal Article
Open access
PDF file
ZSZhixin Sun
Zhixin Sun
JGJacqueline M. Godbe
Jacqueline M. Godbe
AZAlexander Zheleznyak
Alexander Zheleznyak
BMBrad Manion
Brad Manion
JHJunhao Hu
Junhao Hu
MSMonica Shokeen
Monica Shokeen
Radiological imaging plays an indispensable role in both preclinical and clinical studies of multiple myeloma (MM). However, manual quantification in longitudinal small animal PET/CT is limited by annotator bias, signal artifacts from urinary/fecal excretion, and voxel misalignment due to non-rigid registration. To address these challenges and improve characterization of tumor biology, we developed a semi-automated PET/CT quantification pipeline targeting defined regions of interest (ROIs) within the bone marrow-rich mouse skeleton, achieving sub-organ spatial resolution, including in anatomically complex sites such as the pelvis. We applied this MM-specific preclinical pipeline to analyze tumor distribution in a longitudinal molecular PET study using an immunocompetent mouse model of skeletally disseminated MM. An Attention U-Net was trained to segment the thoracolumbar spine, pelvis and pelvic joints, sacrum, and femurs from 2D CT slices. A custom algorithm masked spillover signal from physiological excretion, and a PCA-based projection was used to map tumor distribution along the skeletal axis. Quantification metrics included mean and maximum standardized uptake values (SUVmean, SUVmax) from PET and Hounsfield Units (HU) from CT to assess tumor burden, spatiotemporal tumor distribution, and bone involvement. Tumor burden localized preferentially to skeletal regions near joints. Using precise CT-based alignment (DICE = 0.966 ± 0.005), we detected early disease progression and aggressive phenotypes. A marked increase in tumor uptake was observed by day 18 post-implantation, with significant SUVmean increases in the spine (p = 0.012), left/right femurs (p = 0.007/0.006), pelvis and pelvic joints (p = 0.018), and sacrum (p = 0.02). Notably, sex-based differences were identified: female mice showed greater bone loss near the hip joint at later stages, with significant HUmean reductions at days 25 (p = 0.008) and 32 (p = 0.002). This pipeline enables reproducible, anatomically precise quantification of region-specific trends in MM progression, including joint-specific lesion tropism and sex-based differences, from longitudinal PET/CT scans. By mitigating common challenges such as excretion artifacts and inconsistent mouse positioning, our approach overcomes limitations of manual analysis and enhances evaluation of tumor biology and treatment response in preclinical models of bone-involved cancers.

1 January 2026 in Cancer Research Communications
Verified
Journal Article
Open access
AZAlexander Zheleznyak
Alexander Zheleznyak
DDDhanusha Duraiyan
Dhanusha Duraiyan
PTPrasanth Thunuguntla
Prasanth Thunuguntla
JCJessica Camacho
Jessica Camacho
SWShuang Wu
Shuang Wu
CMChristopher Malone
Christopher Malone
Molecular signatures predict prognosis in hepatocellular carcinoma, but their relevance to transarterial radioembolization (TARE) with yttrium-90 (90Y) is unknown. We aimed to identify baseline and treatment-induced pathways associated with response and nominate biomarkers. Ten transcriptomically diverse human liver cancer cell lines were exposed to escalating activities of glass 90Y microspheres for 10 days. Normalized AUC values quantified sensitivity. Whole-transcriptome RNA sequencing at baseline and after treatment was analyzed with elastic net regression and gene set enrichment. Findings were corroborated by qRT-qPCR and exploratory analysis of pretreatment tumor samples from patients undergoing TARE. Liver cancer cell line responses to 90Y were heterogeneous, with resistance aligning to Hoshida S1 and cholangiocarcinoma-like subtypes. Epithelial–mesenchymal transition (EMT) and adhesion pathways were enriched in resistant lines, with CD44 and ITGA3/α3β1 emerging as candidate markers, corroborated by RNA and protein expression. After 90Y exposure, resistant lines upregulated IFNγ/α, TNFα/inflammatory, and antigen presentation–related pathways, whereas sensitive lines downregulated these pathways along with DNA repair and oxidative phosphorylation. In an exploratory patient cohort, higher tumor CD44 expression trended with early progression. In conclusion, liver cancer cell lines display marked biological heterogeneity in response to 90Y. Baseline EMT/adhesion signatures and stress response pathways nominate CD44 and ITGA3/α3β1 as candidate biomarkers of resistance. These findings delineate molecular programs of β-emitter radioresistance and identify candidate pathways for future targeting. Significance: TARE with 90Y is widely used for liver cancer, yet its molecular determinants of response are poorly understood. Using a diverse panel of liver cancer cell lines, we identify EMT, adhesion, and stress response pathways associated with resistance. These findings highlight candidate biomarkers and molecular vulnerabilities that may guide future therapeutic strategies and patient selection.

11 December 2025
Verified
Other
Open access
DFDouglas V. Faget
Douglas V. Faget
XLXianmin Luo
Xianmin Luo
MIMatthew Inkman
Matthew Inkman
QRQihao Ren
Qihao Ren
XSXinming Su
Xinming Su
SSSheila A. Stewart
Sheila A. Stewart
Contains supplemental figures and legends

22 January 2026
Verified
Other
Open access
AZAlexander Zheleznyak
Alexander Zheleznyak
DDDhanusha Duraiyan
Dhanusha Duraiyan
PTPrasanth Thunuguntla
Prasanth Thunuguntla
JCJessica Camacho
Jessica Camacho
SWShuang Wu
Shuang Wu
CMChristopher Malone
Christopher Malone
Demographics and clinical characteristics of exploratory patient cohort.